JP2013511287A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511287A5
JP2013511287A5 JP2012540160A JP2012540160A JP2013511287A5 JP 2013511287 A5 JP2013511287 A5 JP 2013511287A5 JP 2012540160 A JP2012540160 A JP 2012540160A JP 2012540160 A JP2012540160 A JP 2012540160A JP 2013511287 A5 JP2013511287 A5 JP 2013511287A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
composition according
diabetes
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012540160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511287A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057890 external-priority patent/WO2011063414A1/en
Publication of JP2013511287A publication Critical patent/JP2013511287A/ja
Publication of JP2013511287A5 publication Critical patent/JP2013511287A5/ja
Pending legal-status Critical Current

Links

JP2012540160A 2009-11-23 2010-11-23 ポリペプチド・コンジュゲート Pending JP2013511287A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26375209P 2009-11-23 2009-11-23
US61/263,752 2009-11-23
PCT/US2010/057890 WO2011063414A1 (en) 2009-11-23 2010-11-23 Polypeptide conjugate

Publications (2)

Publication Number Publication Date
JP2013511287A JP2013511287A (ja) 2013-04-04
JP2013511287A5 true JP2013511287A5 (OSRAM) 2013-11-14

Family

ID=44060086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540160A Pending JP2013511287A (ja) 2009-11-23 2010-11-23 ポリペプチド・コンジュゲート

Country Status (11)

Country Link
US (1) US20140066370A1 (OSRAM)
EP (1) EP2504021A4 (OSRAM)
JP (1) JP2013511287A (OSRAM)
KR (1) KR20120116942A (OSRAM)
CN (1) CN102781458A (OSRAM)
AU (1) AU2010321587A1 (OSRAM)
CA (1) CA2781672A1 (OSRAM)
IL (1) IL219948A0 (OSRAM)
MX (1) MX2012005912A (OSRAM)
RU (1) RU2012126101A (OSRAM)
WO (1) WO2011063414A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945499B (zh) * 2014-03-31 2019-12-10 博瑞生物医药(苏州)股份有限公司 结构修饰的glp-1类似物及其制备方法
TWI802396B (zh) * 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN106554404B (zh) * 2015-09-25 2020-11-20 博瑞生物医药(苏州)股份有限公司 艾塞那肽修饰物及其用途
EP4175980A1 (en) * 2020-07-02 2023-05-10 Sanofi Glp-1r agonistic peptides with reduced activity
TW202440619A (zh) 2020-12-18 2024-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69921102T2 (de) 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
DK1143989T3 (da) 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
JP2008500281A (ja) 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ,インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
US7465234B2 (en) * 2004-09-13 2008-12-16 The Boeing Company Hybrid fastening system and associated method of fastening
WO2006086769A2 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
JP2009504681A (ja) * 2005-08-11 2009-02-05 アミリン・ファーマシューティカルズ,インコーポレイテッド 選択可能な特性を有するハイブリッドポリペプチド
EP2330124B1 (en) * 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
JP2009523177A (ja) 2006-01-11 2009-06-18 ブリストル−マイヤーズ スクイブ カンパニー ヒトグルカゴン様ペプチド−1調節因子、並びに糖尿病および関連症状の治療におけるその使用
AU2006341375B2 (en) 2006-03-31 2013-03-21 Amylin Pharmaceuticals, Llc Amylin and amylin agonists for treating psychiatric diseases and disorders
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
AU2007267833B2 (en) * 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
CN102827284B (zh) 2006-11-14 2015-07-29 上海仁会生物制药股份有限公司 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2010118384A2 (en) * 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
WO2012036962A2 (en) * 2010-09-13 2012-03-22 Amylin Pharmaceuticals, Inc. C-terminal amidation of polypeptides
US10755005B1 (en) 2015-12-31 2020-08-25 Dassault Systemes Solidworks Corporation Providing a single command to create multiple CAD features

Similar Documents

Publication Publication Date Title
RU2470016C2 (ru) Производное бипиразола
TWI735546B (zh) 使用fxr促效劑之方法
JP2006143751A5 (OSRAM)
JP2011503152A5 (OSRAM)
JP2017505284A5 (OSRAM)
JP2009542702A5 (OSRAM)
JP2009542699A5 (OSRAM)
RU2017145348A (ru) Селективные соединения пептида yy и их применения
JP2013511287A5 (OSRAM)
JP2008007519A5 (OSRAM)
JP2011225596A5 (OSRAM)
JP2018531938A5 (OSRAM)
JP2013509411A5 (OSRAM)
JP2010533705A5 (OSRAM)
JP2013541583A5 (OSRAM)
US20190169148A1 (en) Method for treating pain or associated condition or symptom
JP2020536854A5 (OSRAM)
JP2017526695A5 (OSRAM)
RU2012126101A (ru) Полипептидный конъюгат
JP2015517458A5 (OSRAM)
JP2015508765A5 (OSRAM)
JP2009506043A5 (OSRAM)
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
JP2014500244A5 (OSRAM)